baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ABBVIE INC. DL-,01/ US00287Y1091 /

2024-04-26 4:00:04 PM	Chg. -5.58	Volume	Bid2024-04-26	Ask2024-04-26	Market Capitalization	Dividend Y.	P/E Ratio
150.82EUR	-3.57%	0 Turnover: 0.00	-Bid Size: -	-Ask Size: -	263.68 bill.EUR	-	-

GlobeNewswire 04-25 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

GlobeNewswire 04-25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 04-24 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...

GlobeNewswire 04-23 Leaders from Fortune 100 Best Companies to Work For To Share Insights at For All Summit May 7-9

GlobeNewswire 04-22 TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...

GlobeNewswire 04-22 Anthos Therapeutics Announces Appointment of Bill Meury as CEO

GlobeNewswire 04-19 NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes a...

GlobeNewswire 04-19 Life Science Cares Launches in Switzerland

GlobeNewswire 04-19 Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire 04-19 Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...

GlobeNewswire 04-18 Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial fo...

GlobeNewswire 04-17 Royalty Pharma Declares Second Quarter 2024 Dividend

GlobeNewswire 04-16 Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...

GlobeNewswire 04-16 OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of C...

GlobeNewswire 04-16 Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

GlobeNewswire 04-15 Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...

Newsfile Corp 04-12 Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Acce...

GlobeNewswire 04-09 STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, ...

GlobeNewswire 04-09 Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

GlobeNewswire 04-08 Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...

GlobeNewswire 04-08 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...

GlobeNewswire 04-06 Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...

GlobeNewswire 04-03 Sig Kirk Joins Assertio Board of Directors

GlobeNewswire 04-02 Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over P...

GlobeNewswire 04-02 Abivax reports 2023 financial results and operational update

ABBVIE INC. DL-,01/ US00287Y1091 /

If you wish to receive reply to your feedback, please provide your email address.